Published in Medical Letter on the CDC and FDA, March 9th, 2003
"pSINCP-85A was highly immunogenic in mice and gave enhanced long-term protection against M. tuberculosis compared with the conventional vector," reported Joanna R. Kirman and her colleagues at the National Institutes of Health, the Food and Drug Administration, and Chiron Corporation.
Kirman and her coauthors published the results of their study in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.